We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Below we will list the departments and units that form part of Vall d’Hebron Hospital and the main diseases that we treat. We will also make recommendations based on advice backed up by scientific evidence that has been shown to be effective in guaranteeing well-being and quality of life.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Speaker: Javier Francisco Ramon Pasías, Postdoctoral researcher Neuromuscular and Mitochondrial Pathology, Vall Hebron Institut de Recerca (VHIR)
Dr. Javier Ramón received his degree in Biomedical sciences in 2015 from the Universitat de Lleida. On his degree he studied the role of the human protein hSPCA1 in calcium and manganese homeostasis using S.cerevisiae as a model. Later, he obtained a master in Advanced microbiology from Universitat de Barcelona and he studied the molecular epidemiology of the human circulating coronaviruses in Hospital Universitari Vall d’Hebron. Then, he stayed in CABIMER (Seville) studying the role of some proteins in double strand break repair through DNA end resection. Finally, in 2018, he incorporated in neuromuscular and mitochondrial pathology lab in Institut de Recerca Vall d’Hebron where he obtained his PhD in 2024 and where he is currently working on treatment of mitochondrial DNA depletion and multiple deletion syndromes using deoxyribonucleosides.
Mitochondrial DNA (mtDNA) depletion and deletions syndromes (MDDS) are diseases characterized by incorrect maintenance of mtDNA resulting in quantitative (depletion) and/or qualitative (multiple deletions and point mutations) alterations of mtDNA. They are rare diseases with heterogeneous clinical presentations (often severe) with no treatment. Deoxyribonucleoside (dN) supplementation was proposed as a treatment for a type of MDDS, the myopathy due to thymidine kinase 2 deficiency (TK2d). This approach showed efficacy in murine models of the disease, in a cohort of patients treated under compassionate basis, and is currently under clinical trial. Subsequently, in vitro studies have shown that dNs also stimulate mtDNA replication in cells with mutations in other MDDS-associated genes possibly by expanding deoxyrinonucleoside triphosphate (dNTP) concentrations and therefore stimulating the mitochondrial replisome. These results suggest that the same therapy approach could be extended to other MDDS forms.
Host: Dr. Ramón Martí Seves, Head of group Neuromuscular and Mitochondrial Pathology, Vall Hebron Institut de Recerca (VHIR)
Online attendance: https://gencat.zoom.us/j/81216982265
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.